Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein

Patent metadata

Field	Value
Publication number	US-10562973-B2
Application number	US-201515129676-A
Country	US
Kind code	B2
Filing date	Apr 8, 2015
Priority date	Apr 8, 2014
Publication date	Feb 18, 2020
Grant date	Feb 18, 2020

Abstract

The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).

First claim

What is claimed is:

1. A blood-brain barrier shuttle comprising:
(a) a humanized brain effector entity antibody comprising three heavy chain CDRs having amino acid sequences of SEQ ID NOS: 10, 11, and 12, respectively, and three light chain CDRs having amino acid sequences of SEQ ID NOS: 25, 26, and 27, respectively; and
(b) a monovalent binding entity that binds to a blood-brain barrier receptor;
wherein the brain effector entity is coupled to the monovalent binding entity.

2. The blood-brain barrier shuttle of claim 1 , wherein the brain effector entity antibody binds to human alpha-synuclein at an epitope consisting essentially of residues 120-122 of SEQ ID NO: 1 and excluding residues 118-119 of SEQ ID NO: 1.

3. The blood-brain barrier shuttle of claim 1 , wherein the brain effector entity antibody binds to human alpha-synuclein at an epitope consisting of residues 120-124 of SEQ ID NO: 1.

4. The blood-brain barrier shuttle of claim 1 , wherein the brain effector entity antibody is of the isotype human IgG1.

5. The blood-brain barrier shuttle of claim 1 , wherein the brain effector entity antibody has at least one mutation in the constant region.

6. The blood-brain barrier shuttle of claim 5 , wherein the mutation reduces complement fixation or activation by the constant region compared to a brain effector entity antibody lacking the at least one mutation.

7. The blood-brain barrier shuttle of claim 1 , wherein the brain effector entity antibody is a Fab fragment, F(ab′)2 fragment, or scFv.

8. The blood-brain barrier shuttle of claim 1 , wherein the monovalent binding entity comprises a blood-brain barrier receptor ligand or antibody fragment.

9. The blood-brain barrier shuttle of claim 8 , wherein the monovalent binding entity comprises an antibody fragment that is a scFv, Fv, scFab, sFab, or VHH.

10. The blood-brain barrier shuttle of claim 9 , wherein the antibody fragment is a sFab.

11. The blood-brain barrier shuttle of claim 8 , wherein the blood-brain barrier receptor is a transferrin receptor, insulin receptor, insulin-like growth factor receptor, low density lipoprotein receptor-related protein 8, low density lipoprotein receptor-related protein 1, or heparin-binding epidermal growth factor-like growth factor receptor.

12. The blood-brain barrier shuttle of claim 11 , wherein the blood-brain barrier receptor is a transferrin receptor.

13. The blood-brain barrier shuttle of claim 12 , wherein the monovalent binding entity comprises a sFab that specifically binds to a transferrin receptor.

14. The blood-brain barrier shuttle of claim 13 , wherein the sFab binds to an epitope within SEQ ID NO: 43, SEQ ID NO: 44, and/or SEQ ID NO: 45.

15. The blood-brain barrier shuttle of claim 1 , wherein the brain effector entity is coupled to the monovalent binding entity by a first linker.

16. The blood-brain barrier shuttle of claim 15 , wherein the first linker is a peptide linker.

17. The blood-brain barrier shuttle of claim 16 , wherein the peptide linker has a length of at least 20 amino acids.

18. The blood-brain barrier shuttle of claim 17 , wherein the peptide linker has a length of 25 to 50 amino acids.

19. The blood-brain barrier shuttle of claim 17 , wherein the peptide linker has an amino acid sequence of SEQ ID NO: 41, 42 or 73.

20. The blood-brain barrier shuttle of claim 15 , wherein the monovalent binding entity is coupled to the C-terminal end of a heavy chain of the brain effector entity antibody by the first linker.

21. The blood-brain barrier shuttle of claim 1 , wherein the monovalent binding entity comprises a CH2-CH3 Ig entity and a sFab that specifically binds to the blood-brain barrier receptor, wherein the sFab is coupled to the C-terminal end of the CH2-CH3 Ig entity.

22. The blood-brain barrier shuttle of claim 1 , wherein:
(a) the monovalent binding entity comprises a CH2-CH3 Ig entity and a sFab that specifically binds to the blood-brain barrier receptor;
(b) a first linker couples the N-terminal end of the CH2-CH3 Ig domain to the brain effector entity; and
(c) a second linker couples the C-terminal end of the CH2-CH3 Ig domain to the sFab.

23. The blood-brain barrier shuttle of claim 21 , wherein the CH2-CH3 Ig entity is a CH2-CH3 IgG entity.

24. The blood-brain barrier shuttle of claim 1 , wherein the brain effector entity antibody includes the Fc region of a heavy chain, and wherein the monovalent binding entity is coupled to the C-terminal end of the Fc region of the heavy chain.

25. The blood-brain barrier shuttle of claim 24 , wherein the brain effector entity antibody comprises two heavy chains, and wherein the monovalent binding entity is coupled to the C-terminal end of the Fc region of only one of the heavy chains.

26. The blood-brain barrier shuttle of claim 24 , wherein the brain effector entity antibody comprises a heterodimerized heavy chain comprising first and second dimerization modules, and only one the first and second dimerization modules is coupled to the monovalent binding entity.

27. The blood-brain barrier shuttle of claim 26 , wherein the first dimerization module comprises knobs and the second dimerization module comprises holes to receive the knobs.

28. The blood-brain barrier shuttle of claim 24 , wherein:
(a) the brain effector entity antibody comprises an IgG heavy chain including an Fc region;
(b) the monovalent binding entity comprises a sFab;
(c) the C-terminal end of the Fc region of the brain effector entity antibody heavy chain is coupled to the N-terminal end of the variable light chain domain of the sFab; and
(d) the C-terminal end of the C-kappa light chain domain of the sFab is coupled to the N-terminal end of the variable heavy chain domain of the sFab.

29. A pharmaceutical composition comprising a blood-brain barrier shuttle of claim 1 and a pharmaceutically acceptable carrier.

30. A blood-brain barrier shuttle comprising:
(a) a brain effector entity comprising an antibody comprising a mature heavy chain variable region having an amino acid sequence at least 90% identical to H4 (SEQ ID NO: 17) and comprising three heavy chain CDRs having amino acid sequences of SEQ ID NOS: 10, 11, and 12, respectively, and a mature light chain variable region having an amino acid sequence at least 90% identical to L3 (SEQ ID NO: 31) and comprising three light chain CDRs having amino acid sequences of SEQ ID NOS: 25, 26, and 27, wherein the antibody specifically binds to human alpha-synuclein; and
(b) a monovalent binding entity that binds to a blood-brain barrier receptor;
wherein the brain effector entity is coupled to the monovalent binding entity.

31. The blood-brain barrier shuttle of claim 30 , provided at least one of positions 11, 27, 30, 48, and 73 of SEQ ID NO:17 is occupied by L, Y, T, I, and K, respectively, and at least one of positions 12 and 14 of SEQ ID NO: 31 is occupied by S.

32. The blood-brain barrier shuttle of claim 31 , provided positions 11, 27, 30, 48, and 73 of SEQ ID NO:17 are occupied by L, Y, T, I, and K, respectively, and positions 12 and 14 of SEQ ID NO: 31 are occupied by S.

33. The blood-brain barrier shuttle of claim 30 , provided at least one of positions 67, 69 and 94 of SEQ ID NO: 17 is occupied by A, L, and S, respectively.

34. The blood-

Assignees

• Prothena Bioscience Ltd
• Hoffmann La Roche

Inventors

• Barbour Robin
• Games-Thiel Kate Dora
• Niijar Tarlochan S
• Zago Wagner
• Mundigl Olaf
• Niewoehner Jens
• Tiefenthaler Georg

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07K2317/64

  comprising a combination of variable region and constant region components · CPC title

• C07K2317/31

  multispecific · CPC title